Abbott Labs Path To Double-Digit Earnings Growth In 2025? This Analyst Is Optimistic
Portfolio Pulse from Vandana Singh
Abbott Laboratories reported strong Q3 results with sales of $10.64 billion, beating expectations. The company projects continued growth, with a robust product pipeline expected to drive earnings growth into 2025. William Blair maintains an Outperform rating on Abbott, citing attractive valuation and potential EPS upside.
October 17, 2024 | 6:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbott Laboratories reported Q3 sales of $10.64 billion, exceeding expectations. The company forecasts continued growth, with a robust product pipeline expected to drive earnings growth into 2025. William Blair maintains an Outperform rating, citing attractive valuation and potential EPS upside.
Abbott's strong Q3 performance and optimistic future projections, including a robust product pipeline and potential for double-digit earnings growth, are positive indicators for the stock. The Outperform rating by William Blair further supports a bullish outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100